Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Sehn, Laurie H.; Herrera, Alex F.; Flowers, Christopher R.; Kamdar, Manali; McMillan, Andrew; Hertzberg, Mark; Assouline, Sarit; Kim, Tae Min; Kim, Won Seog; Özcan, Muhıt; Hirata, Jamie; Penuel, Elicia; Paulson, Joseph N.; Cheng, Ji; Ku, Grace; Matasar, Matthew J.

doi:10.1200/jco.19.00172

articleJournal of Clinical OncologyNov 6, 2019HYBRID OA

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

LHLaurie H. Sehn AFAlex F. Herrera CRChristopher R. Flowers MKManali Kamdar AMAndrew McMillan

University of British Columbia · Spinal Cord Injury BC · +20 more institutions

PubMed

Indexed incrossrefpubmed

Abstract

PURPOSE Patients with transplantation-ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) fare poorly, with limited treatment options. The antibody-drug conjugate polatuzumab vedotin targets CD79b, a B-cell receptor component. METHODS Safety and efficacy of polatuzumab vedotin with bendamustine and obinutuzumab (pola-BG) was evaluated in a single-arm cohort. Polatuzumab vedotin combined with bendamustine and rituximab (pola-BR) was compared with bendamustine and rituximab (BR) in a randomly assigned cohort of patients with transplantation-ineligible R/R DLBCL (primary end point: independent review committee [IRC] assessed complete response [CR] rate at the end of treatment). Duration of…

Citation impact

765

total citations

FWCI: 56.46
Percentile: 100%
References: 23

Citations per year

Authors

16

Topics & keywords

Topics

Keywords

Medicine
Internal medicine
Bendamustine
Rituximab
Neutropenia
Hazard ratio
Cohort
Diffuse large B-cell lymphoma

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.